Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Overall and per-treatment-group patient baseline characteristics

From: A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

Baseline characteristics Overall no. of patients (%) Arm A (%) Arm B (%) Arm C (%)
Total 19 5 8 6
Age     
 Median 60 51 57.5 61.5
 Range 27–86 27–71 50–86 47–77
Sex     
 Male 6 (32) 1 (20) 4 (50) 1 (17)
 Female 13 (68) 4 (80) 4 (50) 5 (83)
ECOG Performance Status     
 0 10 2 4 4
 1 9 3 4 2
Stage at Trial Entry     
 No evidence of disease 4 (21) 2 (40) 0 (0) 2 (33)
 Locally advanced 1 (5) 0 (0) 0 (0) 1 (17)
 Metastatic* 14 (74) 3 (60) 8 (100) 3 (50)
Prior Therapy     
 Chemotherapy alone 5 1 3 1
 Chemotherapy/RT alone 2 0 1 1
 Surgery total 12 4 4 4
  Surgery followed by chemotherapy 7 3 2 2
5 1 2 2
  Surgery followed by chemo/RT
Prior surgical resection     
 Yes 12 (63) 4 (80) 4 (50) 4 (67)
 No 7 (37) 1 (20) 4 (50) 2 (33)
Serum CEA at trial initiation (ng/mL)     
 Median 4.8 5.3 4.65 7.95
 Range 1–246.7 1.1–34.2 2.1–246.7 1–18.1
Serum CA-19-9 at trial initiation (ng/mL)     
 Median 532 22 1067 27
 Range 3–96,900 3–2,710 3–96,900 3–30,300
  1. Abbreviation: Chemo/RT = chemotherapy in combination with radiation;
  2. * All received previous chemotherapy.